AK112
Phase 2Completed 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Gynecologic Cancer
Conditions
Gynecologic Cancer, Cancer Metastatic, Ovarian Neoplasms, Cervical Neoplasm, Endometrial Neoplasms
Trial Timeline
Apr 9, 2021 → May 10, 2024
NCT ID
NCT04870177About AK112
AK112 is a phase 2 stage product being developed by Akeso for Gynecologic Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT04870177. Target conditions include Gynecologic Cancer, Cancer Metastatic, Ovarian Neoplasms.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (7)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07158840 | Phase 2 | Recruiting |
| NCT07010263 | Phase 3 | Recruiting |
| NCT05432492 | Phase 2 | Completed |
| NCT04900363 | Phase 1/2 | Completed |
| NCT04870177 | Phase 2 | Completed |
| NCT04597541 | Phase 1/2 | Completed |
| NCT04047290 | Phase 1 | Completed |
Competing Products
13 competing products in Gynecologic Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| IMGN151 + Carboplatin + Bevacizumab + Olaparib | AbbVie | Phase 2 | 52 |
| Durvalumab + Tremelimumab | AstraZeneca | Phase 1 | 33 |
| Pembrolizumab | Merck | Phase 1 | 33 |
| Atezolizumab + Rucaparib | Roche | Phase 1 | 33 |
| Vigil + Atezolizumab | Roche | Phase 2 | 52 |
| darbepoetin alfa + recombinant human erythropoietin (rHuEPO) | Amgen | Phase 2 | 51 |
| Oral apixaban + Subcutaneous enoxaparin | Bristol Myers Squibb | Phase 2 | 51 |
| Ciprofol + Propofol | Haisco Pharmaceutical Group | Phase 3 | 74 |
| Floseal | Baxter | Phase 3 | 74 |
| FloSeal application | Baxter | Pre-clinical | 20 |
| IPH2201 | Innate Pharma | Phase 1 | 25 |
| Neoantigen specific TCR-T cell drug product + Aldesleukin (IL-2) | Alaunos Therapeutics | Phase 1/2 | 33 |
| Neoantigen specific TCR-T cell drug product | Alaunos Therapeutics | Pre-clinical | 15 |